Everything below concerns thymosin beta-4. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 4963 Da for full-length thymosin beta-4 | Value applies to the parent protein; fragment products may differ |
| Appearance | White to off-white lyophilized powder | Typical form of supplied synthetic peptide |
| Solubility | Freely soluble in water | Polar peptide; dissolves readily in aqueous buffer |
| Storage of dry powder | −20 °C, desiccated, protected from light | Standard laboratory practice for peptides |
| Typical detection method | Liquid chromatography–tandem mass spectrometry | Used in purity testing and anti-doping analysis |
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
=== Family history === A family history of end-stage renal disease with hearing impairment is suggestive of Alport syndrome, but other conditions can cause this combination of abnormalities. Most can be distinguished by clinical features. The finding of haematuria in relatives is suggestive. While X-linked inheritance is the most common pattern, genetic testing is revealing that atypical presentations may be more common than currently thought.
== Protein adducts == 4-HNE can attach to proteins via a Michael addition reaction, which can target cysteine, histidine or lysine, or through the formation of a Schiff base, which can target arginine or lysine. The lysine adduct ((4-HNE)-lysine or 4-hydroxynonenallysine) has been referred to as an "oxidation-specific epitope" and a lipid oxidation "degradation product". It is generated by the oxidative modification of low-density lipoprotein through the direct addition of carbonyl groups from 4-HNE onto lysine.
=== Pantoprazole === The story of pantoprazole's discovery is a good example of the stepwise development of PPIs. The main focus of modification of timoprazole was the benzimidazole part of its structure. Addition of a trifluoromethyl group to the benzimidazole moiety led to a series of very active compounds with varying solution-stability. In general fluoro substituents were found to block metabolism at the point where they were attached. Later the more balanced fluoroalkoxy substituent, instead of the highly lipophilic and strongly electron-withdrawing trifluoromethyl substituent, led to highly active compounds with supposed longer half-lives and higher solution stability. It was realized that activity was somehow linked to instability in solution and then came to the conclusion that the cyclic sulfenamides, formed in acidic conditions, were the active principle of the PPIs. Finally, it was understood that seemingly small alterations in the backbone of timoprazole led nowhere, and focus had to be centered on the substituents on the backbone. However, necessary intramolecular rearrangement of the benzimidazole into sulfenamide posed severe geometric constraints. Optimal compounds would be those that were stable at neutral pH but were quickly activated at low pH. A clear-cut design of active inhibitors was still not possible because in the complex multi-step chemistry the influence of a substituent on each step in the cascade could be different, and therefore not predictable for the overall rate of the prerequisite acid activation.
Sources: en.wikipedia.org
Vaccine refrigerators are designed to store vaccines and other medical products at a stable temperature to ensure they do not degrade. In developing countries with a sunny climate, solar-powered vaccine refrigerators are common.
The history of ornithology largely reflects the trends in the history of biology, as well as many other scientific disciplines, including ecology, anatomy, physiology, paleontology, and more recently, molecular biology. Trends include the move from mere descriptions to the identification of patterns, thus towards elucidating the processes that produce these patterns. Since its modern views through scientific consensus of ornithology in the 21st century, birds are specifically descendants of small, feathered, maniraptoran theropods, which emerged from dinosaurs from the Jurassic period, 160 million years ago.
=== EC 2.1.2: Hydroxymethyl-, Formyl- and Related Transferases === EC 2.1.2.1: glycine hydroxymethyltransferase EC 2.1.2.2: phosphoribosylglycinamide formyltransferase 1 EC 2.1.2.3: phosphoribosylaminoimidazolecarboxamide formyltransferase EC 2.1.2.4: glycine formimidoyltransferase EC 2.1.2.5: glutamate formiminotransferase EC 2.1.2.6: deleted, included in EC 2.1.2.5 EC 2.1.2.7: D-alanine 2-hydroxymethyltransferase EC 2.1.2.8: deoxycytidylate 5-hydroxymethyltransferase EC 2.1.2.9: methionyl-tRNA formyltransferase EC 2.1.2.10: aminomethyltransferase EC 2.1.2.11: 3-methyl-2-oxobutanoate hydroxymethyltransferase EC 2.1.2.12: now EC 2.1.1.74 EC 2.1.2.13: UDP-4-amino-4-deoxy-L-arabinose formyltransferase EC 2.1.2.14: GDP-perosamine N-formyltransferase
=== Homonuclear nuclear magnetic resonance === With unlabelled protein the usual procedure is to record a set of two-dimensional homonuclear nuclear magnetic resonance experiments through correlation spectroscopy (COSY), of which several types include conventional correlation spectroscopy, total correlation spectroscopy (TOCSY) and nuclear Overhauser effect spectroscopy (NOESY). A two-dimensional nuclear magnetic resonance experiment produces a two-dimensional spectrum. The units of both axes are chemical shifts. The COSY and TOCSY transfer magnetization through the chemical bonds between adjacent protons. The conventional correlation spectroscopy experiment is only able to transfer magnetization between protons on adjacent atoms, whereas in the total correlation spectroscopy experiment the protons are able to relay the magnetization, so it is transferred among all the protons that are connected by adjacent atoms. Thus in a conventional correlation spectroscopy, an alpha proton transfers magnetization to the beta protons, the beta protons transfers to the alpha and gamma protons, if any are present, then the gamma proton transfers to the beta and the delta protons, and the process continues. In total correlation spectroscopy, the alpha and all the other protons are able to transfer magnetization to the beta, gamma, delta, epsilon if they are connected by a continuous chain of protons. The continuous chain of protons are the sidechain of the individual amino acids.
Sources: en.wikipedia.org
Neil Alan Dickson, MBE. Co-Founder, The Brain Tumour Charity. For services to People with Brain Tumours. Andrew James Dixon. Founding Trustee, Woodhaven Trust and Fairer Share and Founder, Arc InterCapital. For services to Prisoners and Ex-Offenders, to Property Tax Reform and to Entrepreneurship. Josephine Naomi Clare Dobrin. Co-Founder and Executive Chair, Creative Access. For services to the Creative Industries. Jonathan Donaghy. Deputy Director, Customs, HM Treasury. For Public Service. Amy Louise Doncaster. Deputy Director, Strategy and Future Design, Department for Work and Pensions. For Public Service. Terence Anthony Donnelly. Executive Chair, Donnelly Motor Group and Director, Taxi and Bus Conversions Ltd. For services to the Motor Industry in Northern Ireland. Professor Carol Ann Doyle. Lately Head of School for Nursing and Midwifery Education, Birmingham City University. For services to Nurse Education. Rachael Louise Doyle (Rachael Mills). Director, SE2 and Chirpy Heat. For services to Energy Efficiency and to Diversity and Inclusion. Philip Stephen Dudderidge. Co-Founder and Chair, Focusrite plc. For services to Business and to the Music Industry. Andrew Grant Duncan, DL. For services to the community in Worcestershire. Michael George Eakin. Chief Executive, Royal Liverpool Philharmonic. For services to Music and to the community in Liverpool, Merseyside. Catherine Louise Edwards. Lately Clinical Programmes Director, National Specialised Commissioning, NHS England. For services to the NHS. Emrys Shaun Elias.
Reduction, alkylation, and enzymatic digestion have also shown robustness and reproducibility utilizing DMF, indicating potential in the synthesis and manipulation of proteomics. Spectra obtained from the products of these reactions are often identical to their library spectra, while only utilizing a small fraction of bench-scale reactants. Thus, conducting these syntheses on the microscale has the benefit of limiting money spent on purchasing reagents and waste products produced while yielding desirable experimental results. However, numerous challenges need to be overcome to push these reactions to completion through DMF. There have been reports of reduced efficiency in chemical reactions as compared to bench-scale versions of the same syntheses, as lower product yields have been observed. Furthermore, since picoliter and nanoliter size samples must be analyzed, any instrument used in analysis needs to be high in sensitivity. In addition, system setup is often difficult due to extensive amounts of wiring and pumps that are required to operate microchannels and reservoirs. Finally, samples are often subject to solvent evaporation which leads to changes in volume and concentration of reactants, and in some cases reactions to not go to completion. The composition and purity of molecules synthesized by DMF are often determined utilizing classic analytical techniques. Nuclear magnetic resonance (NMR) spectroscopy has been successfully applied to analyze corresponding intermediates, products, and reaction kinetics.
=== Pharmacokinetics === The high lipid-solubility of cannabinoids results in their persisting in the body for long periods of time. Even after a single administration of THC, detectable levels of THC can be found in the body for weeks or longer (depending on the amount administered and the sensitivity of the assessment method). Investigators have suggested that this is an important factor in marijuana's effects, perhaps because cannabinoids may accumulate in the body, particularly in the lipid membranes of neurons.
==== Increasing fiber intake ==== Fruits and vegetables are two sources of fiber as discussed above. Dietary fiber has been suggested to aid weight management by inducing satiety, decreasing absorption of macronutrients and promoting secretion of gut hormones. Dietary fiber consists of non-digestible carbohydrates and lignin, which are a structural component in plants.
== Use as a lipid biomarker == Tetrahymanol has been found in many marine ciliates at relatively high concentrations, suggesting it may be a useful biomarker in the Earth's rock record. During diagenesis, the alcohol functional group is lost and tetrahymanol becomes gammacerane. Like other saturated triterpenoid skeletons, gammacerane is a highly stable molecule that can preserved in rocks on geological timescales. The oldest gammacerane biomarker was found in a rock 850 million years old. Based on microbial physiology studies, gammacerane was suggested as a potential biomarker for ocean stratification. When water columns stratify, anoxic conditions can form in the bottom waters. Ciliates living in these conditions must adapt to produce lipids that do not require molecular oxygen for their biosynthesis. A direct correlation between sterol availability and tetrahymanol synthesis in ciliates has been shown, leading to the hypothesis that gammacerane in sediments is a biomarker for ocean stratification. This hypothesis was later met with skepticism. While tetrahymanol had mostly been observed in ciliates, several bacteria were then shown to synthesize the lipid and many bacteria across multiple phyla had the gene for tetrahymanol synthase. This evidence has been used to question the potential of gammacerane as a biomarker for water column stratification. For instance, aerobic methanotrophic bacteria were shown to synthesize tetrahymanol. Thus it is not solely a response to anoxic environments.
Sources: en.wikipedia.org
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.
No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.
It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.
Sealed, desiccated and protected from light, at -20 °C or lower for long-term storage. Short-term storage at refrigerator temperature is common in working laboratories.